Clinical Medical Research Center, the Second Clinical Medical College of Jinan University, Shenzhen People's Hospital, Shenzhen, Guangdong Province, China.
Indian J Med Res. 2012 Mar;135(3):305-11.
BACKGROUND & OBJECTIVES: At present, the diagnosis of nephrotic syndrome (NS) requires a renal biopsy which is an invasive procedure. We undertook this pilot study to develop an alternative method and potential new biomarkers for diagnosis, and validated a set of well-integrated tools called ClinProt to investigate serum petidome in NS patients.
The fasting blood samples from 49 patients diagnosed with NS by renal biopsy, including 17 mesangial proliferative glomerulonephritis (MsPGN), 12 minimal change nephrotic syndrome (MCNS), 10 focal segmental glomerulosclerosis (FSGS) and 10 membranous nephropathy (MN), were collected and screened to describe their variability of the serum peptidome. The results in NS group were compared with those in 10 control healthy individuals. Specimens were purified with magnetic beads-based weak cation exchange chromatography and analyzed in a MALDI-TOF MS.
The results showed 43, 61, 45 and 19 differential peptide peaks in MsPGN, MCNS, MN and FSGS groups, respectively. A Genetic Algorithm was used to set up the classification models. Cross validation of healthy controls from MsPGN, MCNS, MN and FSGS was 96.18, 100, 98.53 and 94.12 per cent, respectively. The recognition capabilities were 100 per cent.
INTERPRETATION & CONCLUSIONS: Our results showed that proteomic analysis of serum with MALDI-TOF MS is a fast and reproducible approach, which may give an early idea of the pathology of nephrotic syndrome.
目前，肾病综合征（NS）的诊断需要进行肾活检，这是一种有创性的检查。我们开展了这项初步研究，旨在寻找替代方法和潜在的新生物标志物用于诊断，并验证了一组名为 ClinProt 的综合工具，用于研究 NS 患者的血清多肽组。
收集并筛选了 49 例经肾活检诊断为 NS 的患者（包括 17 例系膜增生性肾小球肾炎（MsPGN）、12 例微小病变性肾病综合征（MCNS）、10 例局灶节段性肾小球硬化（FSGS）和 10 例膜性肾病（MN））的空腹血样，以描述其血清多肽组的变异性。将 NS 组的结果与 10 例健康对照者进行比较。使用基于磁性珠的弱阳离子交换色谱法对标本进行纯化，并在 MALDI-TOF MS 中进行分析。
结果显示，MsPGN、MCNS、MN 和 FSGS 组分别有 43、61、45 和 19 个差异肽峰。使用遗传算法建立分类模型。MsPGN、MCNS、MN 和 FSGS 健康对照组的交叉验证分别为 96.18%、100%、98.53%和 94.12%。识别能力为 100%。
我们的研究结果表明，基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）的血清蛋白质组分析是一种快速且可重复的方法，它可能为肾病综合征的病理提供早期线索。
